Electrochemical Nanomaterial-based Sensors/Biosensors for Drug Monitoring.

Determining the amount of medication used is essential for correctly managing treatment systems. The unauthorized use of drugs and the importance of determining the absorbed and required dose of drugs in target organs are essential factors that justify the design of new drug monitoring systems. Electrochemical sensors and biosensors based on nanomaterials have been developed for drug monitoring in the past few years. The use of nanomaterials to optimize the analyte detection process and facilitate electron transfer in electrochemical processes has enhanced intermolecular interactions and increased diagnostic sensitivity. Considering this review, in the first part, the evaluation of cancer drugs is examined, which can be used to determine the exact dose of the drug required in different stages of cancer. Accurate monitoring of cancer drugs can increase patient life expectancy, reduce side effects, and increase economic savings. In the next section, sensors and biosensors designed for antibiotics are examined. Accurate measurement of antibiotics for determining the effectiveness of the dose in controlling infections and preventing antibiotic resistance is possible with the help of these drug diagnostic platforms. In the next part, the diagnosis of different hormones is considered. Abnormal amounts (low/high) of hormones cause multiple physiological complications and various disabilities. Therefore, accurate determination of hormone levels can effectively treat hormonal changes. In the last section, other drugs, including drugs and analgesics for which the use of electrochemical diagnostic platforms can significantly help drug distribution and social health systems, are also discussed.

Screen-Printed Technologies Combined with Flow Analysis Techniques: Moving from Benchtop to Everywhere.

Screen-printed electrodes (SPEs) coupled with flow systems have been reported in recent decades for an ever-growing number of applications in modern electroanalysis, aiming for portable methodologies. The information acquired through this combination can be attractive for future users with basic knowledge, especially due to the increased measurement throughput, reduction in reagent consumption and minimal waste generation. The trends and possibilities of this set rely on the synergistic behavior that maximizes both SPE and flow analyses characteristics, allowing mass production and automation. This overview addresses an in-depth update about the scope of samples, target analytes, and analytical throughput (injections per hour, limits of detection, linear range, etc.) obtained by coupling injection techniques (FIA, SIA, and BIA) with SPE-based electrochemical detection.

Development of new dinuclear Fe(III) coordination compounds with in vitro nanomolar antitrypanosomal activity.

Chagas disease is a neglected tropical disease caused by the protozoan pathogen Trypanosoma cruzi. The disease is a major public health problem affecting about 6 to 7 million people worldwide, mostly in Latin America. The available therapy for this disease is based on two drugs, nifurtimox and benznidazole, which exhibit severe side effects, including resistance, severe cytotoxicity, variable efficacy and inefficiency in the chronic phase. Therefore, new drugs are urgently needed. Coordination compounds may be an interesting alternative for antiparasite therapy against Leishmania spp., Toxoplasma gondii and T. cruzi. Herein, we tested the in vitro effect on T. cruzi epimastigotes (Y strain) of two new µ-oxo Fe(III) dinuclear complexes: [(HL1)(Cl)Fe(µ-O)Fe(Cl)(HL2)](Cl)2·(CH3CH2OH)2·H2O (1) and [(HL2)(Cl)Fe(µ-O)Fe(Cl)(HL2)](Cl)2·H2O (2) where HL1 and HL2 are ligands which contain two pyridines, amine and alcohol moieties with a naphthyl pendant unit yielding a N3O coordination environment. Complexes (1) and (2), which are isomers, were completely characterized, including X-ray diffraction studies for complex (1). Parasites were treated with the complexes and the outcome was analyzed. Complex (1) exhibited the lowest IC50 values, which were 99 ± 3, 97 ± 2 and 110 ± 39 nM, after 48, 72 and 120 h of treatment, respectively. Complex (2) showed IC50 values of 118 ± 5, 122 ± 6 and 104 ± 29 nM for the same treatment times. Low cytotoxicity to the host cell LLC-MK2 was found for both complexes, resulting in impressive selectivity indexes of 106 for complex (1) and 178 for (2), after 120 h of treatment. Treatment with both complexes reduced the mitochondrial membrane potential of the parasite. Ultrastructural analysis of the parasite after treatment with complexes showed that the mitochondria outer membrane presented swelling and abnormal disposition around the kinetoplast; in addition, reservosomes presented anomalous spicules and rupture. The complexes showed low nanomolar IC50 values affecting mitochondria and reservosomes, essential organelles for the survival of the parasite. The low IC50 and the high selectivity index show that both complexes act as a new prototype of drugs against T. cruzi and may be used for further development in drug discovery to treat Chagas disease.